Pfizer Inc.

02/11/2019 | Press release | Distributed by Public on 02/11/2019 17:42

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma